Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think they're offering it free at the conference. The PR says that OvaDx® is being offered at $650 per test for research purposes only to advance the forefront of ovarian cancer research. If they get 1000 people to pay they'll make a neat $650,000 to continue the research.
Arrayit Corporation Announces the Product Launch of OvaDx(R)
Source: Arrayit Corporation
Arrayit Corporation Announces the Product Launch of OvaDx(R), the Market's First Pre-Symptomatic Screening Test for Ovarian Cancer
Company to Offer 1,000 Tests at the Annual Meeting of the American Association for Cancer Research
SUNNYVALE, Calif., April 1, 2011 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC) announces today the product launch of OvaDx®, the market's first Pre-Symptomatic Screening Test for Ovarian Cancer. The company is offering the first 1,000 tests to attendees of the 102nd annual meeting of the American Association for Cancer Research (AACR) at the Orange County Convention Center in Orlando, Florida on April 2-6, 2011.
OvaDx® is a sophisticated microarray-based blood test that measures the activation of the immune system in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. OvaDx® is being offered at $650 per test for research purposes only to advance the forefront of ovarian cancer research. OvaDx® can be used to analyze different tumor types and stages, the effectiveness of chemotherapies, biomarker profiles in breast cancer and other epithelial cancers, benign gynecological conditions, the efficacy of ovarian cancer drugs for treatment and prevention, and to benchmark existing tests including CA-125, OVA1®, and transvaginal ultrasound. Conference attendees are encouraged to visit Arrayit at AACR booth #1478 for more information.
Arrayit Chief Executive Officer Rene Schena states, "We are excited about the product launch of OvaDx® as a means of advancing the forefront of ovarian cancer research. This is an important milestone for Arrayit."
Bart, google uses a secret formula for ranking the results of a search. The formula includes how many times a page has been referenced by blogs, how many views the page has, and other factors. Since the Arrayit forum was created 3/30, it is not surprising that it is not appearing anywhere near the top of the search results.
Very pretty for sure. She was chosen by People magazine as one of the 50 Most Beautiful People in the world [1990]. And she's Paul's sister.
She's part of the Arrayit Management team:
Rene’ A. Schena – Chief Executive Officer
Mark Schena Ph.D. – President
Todd J. Martinsky – Executive Vice President
Paul K. Haje – Director of Public Relations
Bill Sklar – Chief Financial Officer
Khrystyne Haje – Company Spokesperson
Another stir form the bear: According to an Arrayit Twitter message their celebrity spokesperson Khrystyne Haje will be at the American Association for Cancer Research Annual Meeting taking place Saturday, April 2 - Wednesday, April 6, 2011, at the Orange County Convention Center in Orlando, Florida. I htink that they are up to something here.
Meet famous actress Khrystyne Haje http://imdb.to/hclfxY at American Association for Cancer Research Annual Meeting Arrayit Booth # 1478
Thanks Bart. And to continue with your hibernating bear excellent analogy, I think the Arrayit bear is starting to stir. Lets wait for the big hungry growl :)
Arrayit website has an Ovarian Cancer Forum section. I don't remember having seen it before tonight. My google alert picked it up tonight.
Among the many questions asked/answered in the forum are these about OvaDx:
What is the Arrayit OvaDx® Pre-Symptomatic Ovarian Cancer Test?
Arrayit Corporation has pioneered a new ovarian cancer screening test known as OvaDx®, which stands for ovarian cancer diagnosis. Based on the latest advances in life sciences technology, OvaDx® uses a sophisticated detection device known as a microarray to detect ovarian cancer as early as 5 years in advance of any overt disease symptoms. OvaDx® has been shown in research studies to detect stage IA tumors with high sensitivity and specificity.
What does OvaDx® detect?
OvaDx® detects a woman’s immune response, which is activated as soon as ovarian cancer cells begin to grow. The immune system identifies ovarian cancer cells as a abnormal condition in the body, and quickly activates an immune response to combat the illness. By measuring the immune response, OvaDx® is able to detect ovarian cancer much earlier than current tests.
How is the OvaDx® testing procedure performed?
OvaDx® is an advanced and non-invasive molecular diagnostics testing procedure. A few drops of blood are drawn and spun at high speed to collect the serum. A small amount of serum is then applied to an OvaDx® microarray to allow binding reactions to occur between the patient's serum molecules and capture agents on the OvaDx® testing substrate. Following the binding step, the test is stained with fluorescent molecules to visualize the captured molecules and a report is generated based on a scanned digital image. Samples that produce positive signals on OvaDx® are scored as positive for ovarian cancer whereas samples that fail to produce positive signals are scored as negative.
When will OvaDx® be available?OvaDx® is currently be used for research purposes only. OvaDx® as a clinical diagnostic test will be available to the public upon FDA approval.
http://arrayit.com/Microarray_Diagnostics/Ovarian_Cancer_Forum/ovarian_cancer_forum.html
Mark is still very optimistic about Arrayit's prospects. He said in an email last month that Arrayit is doing very well and to stay tuned for upcoming press releases.
I believe that ARYC's annual report to the SEC (10K) should be out by March 31st, so maybe we'll learn something there.
Another casualty in the struggle to develop an ovarian cancer diagnostic test.
Largo's GeoPharma files for bankruptcy protection
By MICHAEL SASSO | The Tampa Tribune
Published: March 24, 2011
TAMPA - GeoPharma, a struggling Largo drug company that once touted a novel ovarian cancer test, has filed for bankruptcy protection.
This week, the company filed for Chapter 11 bankruptcy protection in Tampa, which protects a company from creditors while it reorganizes its finances. GeoPharma listed estimated assets of $1 million to $10 million and estimated liabilities of $10 million to $50 million.
GeoPharma, which does business as Innovative Health Products, historically has made and distributed generic drugs, health and beauty products and nutritional supplements from its offices on Bryan Dairy Road. However, it has struggled in recent years and in August sold off its pharmaceutical division, Belcher Pharmaceuticals Inc.
The Nasdaq exchange delisted GeoPharma's stock shares in May, because the company failed to keep a stock price above $1 per share.
In December 2007, the company touted a licensing deal it had struck with the University of South Florida Research Foundation. At the time, the company's executives told the Tribune the deal allowed GeoPharma to create a new test that could detect early-stage ovarian cancer in women, using technology developed by a USF researcher.
A GeoPharma executive was unable to comment Thursday
The 10k is due 3/31. Last year they filed it on 3/31. Expect it on 3/31
This is the Vermillion news from Genomeweb
Vermillion Presents Protein Biomarker Study Supporting OVA2 Ovarian Cancer Test
March 11, 2011
Vermillion this week showed preliminary data from its work with Johns Hopkins University School of Medicine to identify protein biomarkers that could improve the accuracy of its OVA1 test for ovarian cancer.
According to the company, the study, which was presented at the 42nd Annual Meeting on Women's Cancer of the Society of Gynecological Oncologists, examined more than 20 candidate biomarkers, identifying three that added information to CA125, the protein biomarker conventionally used in ovarian cancer diagnosis.
This next-generation version of the test, called OVA2, has been a recent area of focus for Vermillion, with CEO Gail Page during a Q4 earnings call citing it – along with the company's vascular disease diagnostic Vasclir – as one of the key products in its pipeline.
In the registration statement filed with the US Securities and Exchange Commission for a recent $21.8 million public offering, Vermillion noted that the proceeds would be used in part to accelerate trials of OVA2 (GWDN 2/15/2011). In November, the firm received $488,958 through the Qualifying Therapeutic Discovery Project Program to be used in part for the development of the test (PM 11/5/2010).
The OVA2 studies presented this week were conducted by Johns Hopkins professor Zhen Zhang and professor and director of the university's Biomarker Discovery Center Daniel Chan.
"Markers that can improve the clinical specificity of current tools for ovarian cancer detection will enhance our ability to test patients in whom cancer is suspected," Vermillion's chief science officer Eric Fung said in a statement. "These results pave the way for further studies that could lead to additional novel tests in the ovarian cancer space."
The Microsoft project has nothing to do with Arrayit. I got an alert about Arrayit and apparently it grabbed this video because another arrayit video about their manufacturing robot was on the same web page.
Microsoft Techfest projects hope to improve medical diagnostics technology.
One project helps with colon cancer screening, while another interprets CT scans
Automated microarray manufacturing robot showing the patented Arrayit spotting device in action. To learn more contact Todd Martinsky Co-Founder ...
http://www.dailymotion.com/video/xhj0yl_microsoft-techfest-projects-hope-to-improve-medical-diagnostics_tech
I agree that Arrayit is supposed to be further along in the development of OvaDx. And I hope that they finish their clinical trials soon and submit the PMA. I have a lot more money invested in ARYC than in MBCI at this point. But to the best of my knowledge Arrayit has never made a public presentation of their preliminary results to a group of cancer specialists for peer review. And that is what Mabcure is doing this week at the annual meeting of the Society of Gynecological Oncologists (SGO).
considering the positive press releases coming out, you would have expected higher trading volume and higher pps
This PR came out today
http://www.businesswire.com/news/home/20110308006401/en/Mabcure-Study-Results-Ovarian-Cancer-Diagnostic-Blood
March 08, 2011 10:23 AM Eastern Time
Mabcure Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the Society of Gynecological Oncologists
ORLANDO, Fla.--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists (SGO).
The 2011 Annual SGO meeting on Women's Cancer currently underway in Orlando, Florida, will be the first time MabCure has shared its peer reviewed data from a July 2010 study. The study results provide initial clinical proof of concept that MabCure’s ovarian cancer antibodies are capable of distinguishing between ovarian cancer and benign tumors of the ovary with 100% specificity, i.e. no false positives.
MabCure conducted the blinded study of several of its ovarian cancer monoclonal antibodies (MAbs) against 54 different blood samples, in collaboration with Professor Vergote of the Department of Gynecological Oncology at UZ Hospital in Leuven, Belgium. The samples were comprised of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young females and 8 males. Results showed that three of MabCure’s MAbs correctly identified 16 of the 17 ovarian cancers, with a diagnostic sensitivity of 94 percent and 100 percent correct classification of the benign tumors.
MabCure’s proprietary technology is based on re-engineered hybridoma methodology, designed to achieve significant quantitative and qualitative improvements. As such, MabCure is capable of generating more than 10,000 hybridomas over the course of 4-6 weeks compared to classic hybridoma which generates 500-2,000 hybridomas over a period of 4-6 months. Furthermore, MabCure’s proprietary technology preserves the three-dimensional structure of the surface antigens on the cancer cells. This allows the immune system to generate highly specific antibodies against the native antigens (i.e. markers) on the cancer cell. The combination of highly specific antibodies coupled with large output, i.e. large library containing more than 30,000 hybridomas, provides MabCure with the ability to select only a handful of the most highly specific monoclonal antibodies against unique tumor specific antigens (TSA) appearing on targeted cancer cells.
A key feature in MabCure’s antibodies is that they are directed against TSA which are uniquely expressed on cancer cells but not on normal cells. These are distinct from most therapeutic or diagnostic antibodies which target normal antigens that are over-expressed in subsets of patients having certain cancers.
MabCure’s Chief Scientific Officer, Dr. Charles Tackney, who is presenting MabCure’s results at the SGO meeting, stated that “there is a critical need for new diagnostic tools which would allow physicians to quickly and reliably determine a patient’s disease status. MabCure’s results are at a pivotal phase in that process. There is much interest from physicians and researchers alike in the current study, as well as seeing the results of our larger study in progress and the determination of the cellular targets identified by MabCure’s antibodies. Confirmation of initial results and the deployment of a robust and validated immunoassay are an active and exciting part of the conversation at SGO. Our data has certainly generated much interest and promises to deliver on a much needed new medical diagnostic tool for oncologists.”
MabCure intends to expand on this study with a follow-on study of more than 100 blood samples containing ovarian cancer and benign tumors of the ovaries, in collaboration with the Catholic University Hospital, Leuven, Belgium. Both the samples from this study as well as samples from the Company’s clinical study in Thailand are expected to be analyzed concurrently, using highly purified MAbs, during the second quarter of 2011.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which we plan to develop as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website at www.mabcure.com.
Arrayit uses the 'black box" approach to diagnostic tests development where nobody outside the company knows what's going on inside the "box". Mabcure is using more of a "gray box" approach where some information comes out for the world to see and peers to review the information.
Mabcure Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the Society of Gynecological Oncologists
March 8,2011
ORLANDO, Fla.--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists (SGO).
The 2011 Annual SGO meeting on Women's Cancer currently underway in Orlando, Florida, will be the first time MabCure has shared its peer reviewed data from a July 2010 study. The study results provide initial clinical proof of concept that MabCure’s ovarian cancer antibodies are capable of distinguishing between ovarian cancer and benign tumors of the ovary with 100% specificity, i.e. no false positives.
MabCure conducted the blinded study of several of its ovarian cancer monoclonal antibodies (MAbs) against 54 different blood samples, in collaboration with Professor Vergote of the Department of Gynecological Oncology at UZ Hospital in Leuven, Belgium. The samples were comprised of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young females and 8 males. Results showed that three of MabCure’s MAbs correctly identified 16 of the 17 ovarian cancers, with a diagnostic sensitivity of 94 percent and 100 percent correct classification of the benign tumors.
MabCure’s proprietary technology is based on re-engineered hybridoma methodology, designed to achieve significant quantitative and qualitative improvements. As such, MabCure is capable of generating more than 10,000 hybridomas over the course of 4-6 weeks compared to classic hybridoma which generates 500-2,000 hybridomas over a period of 4-6 months. Furthermore, MabCure’s proprietary technology preserves the three-dimensional structure of the surface antigens on the cancer cells. This allows the immune system to generate highly specific antibodies against the native antigens (i.e. markers) on the cancer cell. The combination of highly specific antibodies coupled with large output, i.e. large library containing more than 30,000 hybridomas, provides MabCure with the ability to select only a handful of the most highly specific monoclonal antibodies against unique tumor specific antigens (TSA) appearing on targeted cancer cells.
A key feature in MabCure’s antibodies is that they are directed against TSA which are uniquely expressed on cancer cells but not on normal cells. These are distinct from most therapeutic or diagnostic antibodies which target normal antigens that are over-expressed in subsets of patients having certain cancers.
MabCure’s Chief Scientific Officer, Dr. Charles Tackney, who is presenting MabCure’s results at the SGO meeting, stated that “there is a critical need for new diagnostic tools which would allow physicians to quickly and reliably determine a patient’s disease status. MabCure’s results are at a pivotal phase in that process. There is much interest from physicians and researchers alike in the current study, as well as seeing the results of our larger study in progress and the determination of the cellular targets identified by MabCure’s antibodies. Confirmation of initial results and the deployment of a robust and validated immunoassay are an active and exciting part of the conversation at SGO. Our data has certainly generated much interest and promises to deliver on a much needed new medical diagnostic tool for oncologists.”
MabCure intends to expand on this study with a follow-on study of more than 100 blood samples containing ovarian cancer and benign tumors of the ovaries, in collaboration with the Catholic University Hospital, Leuven, Belgium. Both the samples from this study as well as samples from the Company’s clinical study in Thailand are expected to be analyzed concurrently, using highly purified MAbs, during the second quarter of 2011.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which we plan to develop as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website at www.mabcure.com.
http://www.businesswire.com/news/home/20110308006401/en/Mabcure-Study-Results-Ovarian-Cancer-Diagnostic-Blood
To be fair they mean it will increase LONGTERM share holder value not short term gains. At the moment ARYC is trading listlessly because of the lack of information about the diagnostic tests in the pipeline. That will change some day when announcements are made.
Form 8-K for PROVECTUS PHARMACEUTICALS INC
1-Mar-2011
Regulation FD Disclosure, Financial Statements and Exhibits
Item 7.01. Regulation FD Disclosure.
On March 1, 2011, Craig Dees, PhD, Chief Executive Officer of Provectus Pharmaceuticals, Inc. (the "Company") delivered a presentation to members of the financial community and updated investors on the status of PV-10 and PH-10, the Company's oncology and dermatology therapies currently in development. Dr. Dees noted the Company has scheduled a meeting with the U.S. Food and Drug Administration on March 7, 2011 to discuss the design of a pivotal Phase 3 randomized controlled study of PV-10 for metastatic melanoma suitable for Special Protocol Assessment (SPA). Also on March 1, 2011, the Company issued a press release highlighting clinical developments in 2010 and expectations for the first part of 2011. A copy of the press release updating its shareholders is furnished as Exhibit 99 to this Current Report on Form 8-K
In the PR, Mabcure said that in the second quarter of this year they are relocating their labs to New York City within a network of world class biomedical research centers. That should put more pressure on Arrayit.
"Lastly, we are pleased to inform you that our Board of Directors has approved our plan to relocate MabCure’s lab facilities and executive offices to New York City, within a network of world class biomedical research centers, which we believe will enhance MabCure’s position in the field, present new collaboration opportunities and accelerate R&D. We anticipate that the relocation will be completed during the second quarter of this year, and will not interfere with our ability to achieve our clinical milestones in a timely manner."
Mabcure Corporate update released today. Sounds like they are on the right track.
http://www.businesswire.com/news/home/20110301006392/en/MabCure-Corporate-Update
Mabcure, one of ARYC competitors for ovarian and prostate cancer diagnostic tests, just released a corporate update of their progress. Why can't ARYC do the same?
http://www.businesswire.com/news/home/20110301006392/en/MabCure-Corporate-Update
Bart, you can get free ask/bid quotes on this website:
http://www.otcmarkets.com/stock/aryc/quote
Getting free Real-Time Level 2 Quote Montage
is one of the advantages of ARYC now trading on the OTCQB marketplace.
And I agree with you the pps is trending up. Let's hope it continues that way
Immunotherapy Stocks Show Strong Promise in Fight against Cancer
By Justin Kuepper on Monday, February 28th, 2011
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a biopharmaceutical company focused on cancer and psoriasis treatments using the Rose Bengal compound, along with companies like Dendreon Corporation (Nasdaq: DNDN) and Oncothyreon Inc. (Nasdaq: ONTY), are seeing some promising results using immunotherapy techniques in the fight against cancer.
Renewed Focus on Immunotherapy
Immunotherapy is a treatment that uses the body’s own immune system to fight off a disease by either stimulating the immune system or offering artificial immune system components. While doctors have long suspected the immune system was involved in fighting cancer, it hasn’t been until recently that companies have discovered how to stimulate them to effectively combat the disease.
Dr. William Coley was the first to notice that getting an infection after surgery seemed to help some cancer patients, suggesting that the immune system played a role in combatting cancer. However, the advent of radiation and chemotherapy pushed many of these developments to the back-burner, and only in the last decade has immunotherapy really become an area of focus.
Safer Treatments, Growing Efficacy
Radiation and chemotherapy treatments use high doses of radiation and toxic chemicals to kill cancer cells, but often times catch healthy cells in the crossfire, leading to an overall deterioration in health. Since immunotherapy does not typically use radiation on its own, the treatments are widely considered to be less toxic to patients, and are therefore preferred by most patients.
Unfortunately, most immunotherapy treatments to date are only marginally effective and usually only used on early stage cancers. Some cancer companies are aiming to change this, including Dendreon, Oncothyreon and Provectus Pharmaceuticals. These companies are developing treatments that can help early and late stage types of cancer with significantly higher efficacy than other treatments.
Provectus Offers Best of Both Worlds
Provectus Pharmaceuticals has developed a unique cancer compound called PV-10 that is based on the Rose Bengal compound. While traditionally used as a dye, the biopharmaceutical company discovered that it selectively targeted and killed certain types of cancer cells. In clinical trials to date, the firm has demonstrated significant efficacy and a great safety profile.
Meanwhile, the unique compound has also demonstrated what it calls the “by-stander effect” whereby untreated legions also improve. As a result, the company believes that PV-10 may be stimulating the immune system into fighting cancer on its own, which has led to significant interest in its compound by many cancer researchers around the world
http://biotechstocktrader.com/immunotherapy-stocks-show-strong-promise-in-fight-against-cancer-173/
OTCQB Factsheet
(Note: Pink OTC Markets Announced Official Name Change to OTC Markets Group Inc. Jan 18 , 2011.)
OTCQB: SEC Registered Companies Trading OTC
The OTC equities market in the U.S. has seen rapid changes over the past few years that have made OTC trading more transparent and efficient. OTC Markets Group has been the leader in using
technology to bring positive changes to the OTC market for thebenefit of investors as well as broker-dealers and OTC-traded companies. OTC Markets Group’s electronic interdealer quotation
system has become the leading platform in the U.S. OTC market and many broker-dealers are now exclusively using OTC Markets Group’s platform to quote OTC securities – regardless of their SEC reporting status.
With over 94% of all market maker quotes in OTC securities published on OTC Markets Group’s platform vs. 6% on the FINRA BB, it is important that OTC Markets Group provide a separate
designation to identify OTC-traded companies that are U.S. registered and reporting. OTC Markets Group has launched the OTCQB TM marketplace to help investors easily identify SEC
reporting companies and regulated banks that are current with their disclosure obligations.
What OTC Investors Should Know
• OTC Markets Group segments OTC securities into three tiers: the quality-controlled OTCQX® marketplace, the U.S. reporting OTCQB marketplace, and the OTC Pink marketplace for speculative
trading.
• OTCQB is a market tier for OTC -traded companies that are reporting with the U.S. Securities and
Exchange Commission (SEC) or a U.S. banking or insurance regulator.
• Real-Time Level 2 Quotes for OTCQB securities are available for free to all investors.
• The predominance of OTC Markets Group’s quotation system over the FINRA BB is a direct result of
OTC Markets’ years of investment and dedication to building the best trading technology for brokerdealers
that trade OTC securities; in contrast, the FINRA BB is still a telephonic market
• Market makers increasingly favor OTC Markets Group’s quotation system over the FINRA BB tofacilitate trading in all OTC securities.
This clears the confusion. Yahoo, Scottrade and other financial websites are incorrectly listing ARYC as ARYC:Pink OTC Markets. It should be ARYC:OTCQB.
------------
Per Arrayit Investors relations: Arrayit recently gained a dual listing on the OTCBB and OTCQB (OTO). Some market makers prefer the OTCQB because they can trade electronically rather than over the telephone and because access to second level quotations is free of charge (see attached). They believe the dual listing will have a positive impact on shareholder value by making it easier to trade shares of ARYC
-------------
I found this information....Pink Markets launched the OTCQB Marketplace for U.S. Registered and Reporting OTC Securities
Read below.
OTCQB Marketplace Launched by Pink OTC Markets
New OTC Market Tier Launched for all U.S. Registered and Reporting OTC Securities
NEW YORK, April 5 /PRNewswire-FirstCall/ -- In an effort to better distinguish OTC securities that are registered and reporting with U.S. regulators, Pink OTC Markets Inc. (OTCQX: PINK), today announced the creation of the OTCQB™ marketplace. This new comprehensive OTC market tier will include the securities of over 768 SEC reporting companies and banks formerly designated as Pink Sheets® stocks, in addition to the 3050 securities that are currently quoted in both Pink OTC Markets' electronic interdealer quotation system and FINRA's OTCBB™....
http://www.prnewswire.com/news-releases/otcqb-marketplace-launched-by-pink-otc-markets-89903542.html
You are right OTCmarkets.com says Arrayit Corp. ARYC OTCQB/Common Stock
But Scottrade.com and Yahoo Finance say
Arrayit Corp ARYC:Pink OTC Markets Inc..
http://research.scottrade.com/qnr/Public/Stocks/Snapshot?symbol=aryc
http://finance.yahoo.com/q?s=ARYC.PK
It is confusing.
I contacted investorrelations@arrayit.com
They answered that they are not sure why this change happened. Until they hear back, they are updating the ARYC website to use the NASDAQ stock feed for ARYC rather than the Yahoo finance feed.
That does not sound good. Does it?
From wikipedia:
The Pink Sheets is not a stock exchange. To be quoted in the Pink Sheets, companies do not need to fulfill any requirements (e.g. filing financial statements with the SEC). With the exception of foreign issuers, mostly represented by ADRs, the companies quoted in the Pink Sheets tend to be closely held, extremely small, thinly traded, or bankrupt. Most do not meet the minimum U.S. listing requirements for trading on a stock exchange such as the New York Stock Exchange. Many of these companies do not file periodic reports or audited financial statements with the SEC, making it very difficult for investors to find reliable, unbiased information about those companies.
For these reasons the SEC views companies listed on Pink Sheets as "among the most risky investments"[2] and advises potential investors to heavily research the companies in which they plan to invest.
From investopedia:
The Pink Sheets are different from the OTCBB. Companies on the Pink Sheets are not required to meet minimum requirements or file with the SEC. So-named because they were actually printed on pink paper, the Pink Sheets started out as a daily quote service provided by the National Quotation Bureau. Typically, companies are on the Pink Sheets because either they are too small to be listed on a national exchange or they do not wish to make their budgets and accounting statements public. To avoid having to file with the SEC, some large foreign companies such as Nestle S.A. have penetrated the American securities markets through the Pink Sheets. Companies listed on the Pink Sheets are difficult to analyze because it is tough to obtain accurate information about them. The companies on the Pink Sheets are usually penny stocks and are often targets of price manipulation. They should only be purchased with extreme caution.
I don't know why OTO is in the picture for ARYC now.
All i can find in google is the definition of OTO.
One Triggers Other (OTO) Order
With a One Triggers Other order, you can enter an initial order for a stock, ETF or option, and simultaneously place a second order that’s contingent upon the fill of the first order. That is, with One Triggers Other you are actually placing two orders at once. The first is sent to the market immediately, the second is sent to the market only when the first one is filled.
One Trigger Other orders let you fine-tune your trade’s entry or exit strategy to execute your plan when your specific targets have been reached. It’s a great way to “trade your plan” with discipline, while enjoying the convenience of automated trade entry.
I got it from http://otcbb.com/
Search for symbol ARYC then select the Depth/Level II tab
Starting 2/23 the exchange where ARYC is trading is OTO instead of the usual OBB. Not sure what the difference or implications are. Yahoo Finance does not show activity for ARYC since this change occurred.
ARYC - Time & Sales
Price Size Exch Time
0.29 700 OTO 10:22:37
0.221 4000 OTO 02/24
0.25 5000 OTO 02/24
0.25 2500 OTO 02/24
0.25 2500 OTO 02/24
0.24 1000 OTO 02/24
0.26 3900 OTO 02/24
0.21 750 OTO 02/24
0.25 10000 OTO 02/23
0.24 10000 OTO 02/23
0.28 2000 OBB 02/22
0.29 5000 OBB 02/22
0.29 156 OBB 02/22
0.29 344 OBB 02/22
0.29 1656 OBB 02/22
0.27 5000 OBB 02/22
Do they have to do a 10 Q for the fourth quarter or only a 10 K for the whole 2010 fiscal year?
Yes, a conference call like VRML had yesterday to discuss their quarterly results.
Vermillion Posts $345K in Q4 Revenues
February 10, 2011
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Vermillion today announced revenues of $345,000 for the fourth quarter and $1.2 million for full-year 2010, the first year that its OVA1 triage test for ovarian cancer was commercially available.
For the three months ended Dec. 31, 2010, the Austin, Texas-based molecular diagnostics company posted revenues of $345,000, compared to no revenues a year ago. Wall Street had expected $660,000 for the quarter.
The company received $149,000 in product revenues with the balance, $196,000, comprised of licensing revenues.
During the quarter, 2,935 OVA1 tests were performed, a 49 percent increase over the third quarter. During a conference call following the release of Vermillion's earnings, Chairperson and CEO Gail Page said that the firm is moving closer to launching OVA1 abroad, and has been working with Quest Laboratories, its partner on the test, on launch plans in India, Mexico, and England.
Vermillion, she noted, is set to launch the test in at least one of those countries by mid-year.
In addition, the company is "very excited" by the market opportunity in China and is in discussions with potential partners there.
For the first quarter of 2011, the company expects to perform between 3,000 and 3,500 OVA1 tests, CFO Sandra Gardiner noted on the call.
Page said that the company is progressing with two other tests in its pipeline, one for vascular disease, and the other is the OVA2 test for diagnostic purposes in ovarian cancer not addressed by OVA1.
On the vascular program Vermillion has partnered with the Colorado Prevention Center on an intended-use study. Patient recruitment for the study is expected to begin shortly, Page said, and top-line data is expected to become available in the third quarter.
On OVA2, Vermillion is working with researchers at Johns Hopkins University. "We have undertaken marker assessment studies and have generated encouraging data," which will be presented at a forthcoming conference, she said.
During the quarter, Vermillion spent roughly $1.1 million on R&D, up 26 percent from $831,000 a year ago. SG&A costs rose five-fold to $3.5 million from $669,000 a year ago.
Vermillion's net loss for the fourth quarter was $4.0 million, or $0.38 per share, down 38 percent from a loss of $6.4 million, or $0.86 per share, for Q4 2009, above Wall Street estimates of a loss of $0.35 per share.
For full-year 2010, the company posted revenues of $1.2 million, compared to no revenues in 2009, but below analyst expectations of $1.49 million. Product revenues totaled $308,000, and licensing revenues totaled $867,000.
Its net loss for the year came in at $19 million, or $1.83 per share, down 14 percent from a loss of $22 million, or $3.31 per share, in 2009. Analyst estimates were for a loss of $1.81 per share.
Vermillion's R&D costs were $3.8 million, up from $2.3 million, a 64 percent uptick. SG&A costs rose nearly four-fold to $11.8 million from $3.0 million in 2009.
Vermillion had $22.9 million in cash and cash equivalents as of Dec. 31.
Delays in Approval Send Device Makers to Foreign Markets.
Interesting article in the New York Times. Excerpts below
Medical Treatment, Out of Reach
The New York Times
By ANDREW POLLACK
Published: February 9, 2011
Medical device industry executives and investors are complaining vociferously these days that the industry’s competitive edge in the United States and overseas is being jeopardized by a heightened regulatory scrutiny.
...
The F.D.A., they and others say, appears to be reacting to criticism that its approvals for some products had been lax, leading to a spate of recalls of some unsafe medical devices, like implanted defibrillators and hip replacements.
...
Now, executives of device companies say the F.D.A. has gone too far in flexing its regulatory muscle, and they worry that a slower, tougher approval process in a weakened economy could chill investments and cripple innovation.
Acknowledging industry concerns, the F.D.A. on Tuesday proposed creating an “innovation pathway” aimed at speeding regulatory reviews of a small number of groundbreaking devices. And last month the agency announced measures it said would make the regulatory process more predictable for the vast majority of devices.
“A consistent and predictable review process will stimulate investment here at home and keep jobs from going overseas,” Dr. Jeffery Shuren, the director of the agency’s medical device division, told reporters.
But Dr. Shuren said the F.D.A. would not relax its standards, arguing that Europe’s system might be too lax. He said that a breast implant, a lung sealant and an implant for elbow fractures were approved in Europe but not in the United States, and then had to be taken off the market in Europe for safety reasons.
“We don’t use our people as guinea pigs in the U.S.,” he said
....
Pharmaceutical executives are also complaining about how tough the F.D.A. has become. But they are not forsaking the American market, in part because there is not a big disparity in the regulatory system for drugs between the United States and Europe.
Some figures bear out a toughening in devices. The F.D.A. last year granted 19 premarket approvals — the type of clearance required for the most highly regulated devices — down from 48 in 2000.
The average time to win an approval through the less stringent 510(k) pathway, which is used for most devices, rose to 116 days in fiscal year 2008 from 97 days in fiscal year 2002. Agency figures show there have been increases in the proportion of applications sent back for questioning.
Investment by American venture capitalists in the medical device sector has fallen 37 percent since 2007 to $2.3 billion last year, according to the MoneyTree survey from PwC, the National Venture Capital Association and Thomson Reuters. That is steeper than the 27 percent drop for all venture capital investing.
Last year, total venture capital investing increased 19 percent while investment in medical devices fell 9 percent.
...
The complaints are driven in part by financial pressures. Venture capitalists, because of the financial crisis and their own poor returns, have less money and need quicker returns on their investments from the companies they back.
Bigger device companies also complain about the F.D.A., but not as much as struggling start-ups. “The F.D.A. is asking for larger trials, more thoughtful trials, all in the interest of the American public,” said Dr. Stephen N. Oesterle, senior vice president for medicine and technology at Medtronic.
To be sure, the United States remains the clear world leader in medical device innovation, according to the report by PricewaterhouseCoopers. Some 32 of the 46 medical technology companies with annual sales exceeding $1 billion are based in the United States, the report said.
Still, the report said the United States’ lead was slipping.
Device companies have been seeking early approval in Europe for years because it is easier. In Europe, a device must be shown to be safe, while in the United States it must also be shown to be effective in treating a disease or condition. And European approvals are handled by third parties, not a powerful central agency like the F.D.A
http://www.nytimes.com/2011/02/10/business/10device.html?pagewanted=1&_r=1&sq=medical treatment&st=Search&scp=1
She's Paul Haje's sister. Paul is the ARYC VP of Sales and Marketing. Wonder what her role will be. Commercials for ARYC?
Don't know what to make of this:
Investors - Celebrity Spokesperson - Khrystyne Haje
Arrayit’s celebrity spokesperson is television and film actress Khrystyne Haje.
This link has a giant photo of Khrystyne, and it lists her email as Khrystyne@arrayit.com
http://www.arrayit.com/Microarray_Investor/Arrayit_Corporation_ARYC_Celeb/arrayit_corporation_aryc_celeb.html
The name Haje sounded familiar. Paul Haje is the Vice President Sales and Marketing of Arrayit Corporation, and he used to work in Hollywood.
Point to me on the ARYC website where they discuss the clinical trials that they are conducting for OvaDx (or any of their other diagnostic tests in the pipeline). What hospital, how many patients, duration, preliminary results.
I don't know why Arrayit has to keep everything they do so top secret. It would help if they put out a Fact sheet similar to MBCI's
http://www.wallstreetpoker.com/reports/MCBI.pdf
Nicely written report about MBCI
http://www.wallstreetpoker.com/reports/MCBI.pdf
OUCH!